Radioligand therapy (RLT) exploration is bringing more to the horizon
The number of patients eligible for treatment with RLT is expected to grow exponentially in the coming years
Over 450 clinical and preclinical programs are in development across the industry, indicating the potential of RLT across tumor types1
RLT is being investigated in 421 clinical and preclinical programs across solid tumor types, including2:
- Breast: 26 trials
- Gastrointestinal: 44 trials
- Gynecologic: 157 trials
- Genitourinary: 112 trials
- Lung: 23 trials
- GEP-NET: 27 trials
- Neurologic: 17 trials
- Solid Tumor (broad): 157 trials
RLT is also being investigated in hematologic and other malignancies, where a total of 43 clinical and preclinical programs are underway2
GEP-NET, gastroenteropancreatic neuroendocrine tumor.
Note: Represents all clinical programs planned or underway for RLTs, including those studying multiple tumor types. Data exhibit results of due diligence on 681 unique RLT assets; exclusions from analysis comprise Novartis assets, Azedra® & Xofigo® not fitting RLT definition, Bexxar® & Zevalin® due to discontinued status, and pre-registrational generic assets (Lantheus, PNT2003, and Curium) are not included pending FDA review.
*Other programs include other solid tumors and head and neck programs.
Note: Represents all clinical programs planned or underway for RLTs, including those studying multiple tumor types. Data exhibit results of due diligence on 681 unique RLT assets; exclusions from analysis comprise Novartis assets, Azedra® & Xofigo® not fitting RLT definition, Bexxar® & Zevalin® due to discontinued status, and pre-registrational generic assets (Lantheus, PNT2003, and Curium) are not included pending FDA review.
*Other programs include other solid tumors and head and neck programs.
Hear perspectives from an RLT trailblazer on the future of treatment with RLT
Novartis is advancing new targets across additional tumor types3
- Genitourinary: 11 trials
- GEP-NETs: 2 trials
- Breast: 4 trials
- Lung: 2 trials
- Solid Tumor: 4 trials
*Data as of March 16, 2026. Represents all clinical trials planned or underway for RLTs, including those studying multiple tumor types.
Novartis is expanding and leading RLT research to help more people living with cancer
Hear from an RLT trailblazer about the growth of RLT and the potential to help more patients
References: 1. Data on file. S&G RLT landscape analysis. Novartis Pharmaceuticals Corp; 2024. 2. Data on file. RLT clinical trial analysis. Novartis Pharmaceuticals Corp; 2026. 3. Novartis Pipeline Navigator. Accessed April 6, 2026. https://www.pipelinenavigator.com/pipeline